X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

Pakistanis join final trials for China-made vaccine

Content Team by Content Team
26th November 2020
in Clinical Trials, Drug Development, News
Pakistanis join final trials for China-made vaccine

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Thousands of volunteers are flocking to research hospitals across Pakistan to join final-stage clinical trials of a Chinese-made vaccine for the coronavirus.

It is the first time Pakistan has participated in such a trial, which comes amid a string of positive vaccine announcements by Western pharmaceutical companies this month. The vaccine is being developed by CanSinoBio and the Beijing Institute of Biotechnology China.

“I have volunteered myself for a noble cause that will help humanity,” said a volunteer at Islamabad’s Shifa hospital, where hundreds of participants are being paid about $50 for their trouble.

Others should “step forward and take part in this noble cause which will save lives,” he added. For years, China has focused much of its attention in Pakistan on mammoth development projects, bankrolling the construction of roads, power plants and a strategic port.

Beijing has now tapped one of its closest allies to participate in the vaccine trials, despite Pakistan’s chequered history with inoculation campaigns.

“We hope to have some findings ready about the accuracy and efficacy of the vaccine in two to three months,” Ejaz Ahmad Khan, the principal researcher overseeing the trial in Pakistan, told AFP.

Officials said Pakistan has already inoculated about 7,000 of the 10,000 participants expected to receive a jab. The trials come with intensive care wards across the country nearing capacity as a second, deadlier wave of the coronavirus spreads and officials struggle to counter public indifference to the pandemic.

The country has confirmed more than 382,000 cases including over 7,800 deaths since the virus arrived in late February. Less than a year after the coronavirus that has claimed 1.4 million lives began spreading across the globe, a number of highly promising COVID-19 vaccines are on the cusp of release.

Four separate drug makers have recently announced that their vaccines are effective for most people. Due to lingering suspicions over vaccines, Pakistan is one of just two countries where polio continues to spread, sparking fears that a new drive to inoculate the population against the coronavirus will fail.

The Chinese vaccine is also undergoing phase 3 trials—or large-scale testing on humans—in several other nations including China, Russia, Chile, Argentina and Saudi Arabia.

Previous Post

China Says Ready To Boost Global COVID-19 Vaccine Cooperation

Next Post

US to distribute 6.4 million doses of Pfizer-BioNTech COVID-19 vaccine in first tranche by year-end

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
US to distribute 6.4 million doses of Pfizer-BioNTech COVID-19 vaccine in first tranche by year-end

US to distribute 6.4 million doses of Pfizer-BioNTech COVID-19 vaccine in first tranche by year-end

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In